{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:36:42Z","timestamp":1785785802310,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture gastrointestinal (GI) tract morbidity in patients with systemic sclerosis (SSc). The aims of this study were to determine in a large SSc cohort if the UCLA GIT 2.0 is able to discriminate patients for whom a rheumatologist with experience in SSc would recommend an esophago-gastro-duodenoscopy (EGD), and if it could identify patients with endoscopically proven esophagitis or with any pathologic finding on EGD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We selected patients fulfilling the ACR\/EULAR 2013 criteria for SSc from our EUSTAR center having completed at least once the UCLA GIT 2.0 questionnaire, and we collected data on gastrointestinal symptoms and EGD from their medical charts. We analyzed by general linear mixed effect models several parameters, including UCLA GIT 2.0, considered as potentially associated with the indication of EGD, as well as with endoscopic esophagitis and any pathologic finding on EGD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 346 patients (82.7% female, median age 63\u2009years, median disease duration 10\u2009years, 23% diffuse cutaneous SSc) satisfying the inclusion criteria, who completed UCLA GIT 2.0 questionnaires at 940 visits. EGD was recommended at 169 visits. In multivariable analysis, UCLA GIT 2.0 and some of its subscales (reflux, distention\/bloating, social functioning) were associated with the indication of EGD. In 177 EGD performed in 145 patients, neither the total ULCA GIT 2.0 score nor any of its subscales were associated with endoscopic esophagitis, nor with any pathologic EGD findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-life setting, the UCLA GIT 2.0 and its reflux subscale were able to discriminate patients with SSc who had an indication for EGD, but did not correlate with findings in EGD. We conclude that, while using the UCLA GIT 2.0 in the routine care of patients with SSc may help the rheumatologist to better understand the burden of GI symptoms in the individual patient, it should not be used as a stand-alone instrument to identify an indication of EGD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02506-x","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T03:04:39Z","timestamp":1619060679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Norina","family":"Zampatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Garaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucsandra","family":"Dobrota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Oliver","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-8817","authenticated-orcid":false,"given":"Carina","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"8","key":"2506_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FMP Meier","year":"2012","unstructured":"Meier FMP, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, M\u00fcller-Ladner U, EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200742.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2506_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Air\u00f2 P, Joven B, Vettori S, Cozzi F, Ullman S, Czirj\u00e1k L, Tikly M, M\u00fcller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Sz\u00fccs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, M\u00fcller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, M\u00fchlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, de Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, Garc\u00eda de la Pe\u00f1a Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y, EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897\u2013905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2506_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1751-2980.12720","volume":"20","author":"H Yang","year":"2019","unstructured":"Yang H, Xu D, Li MT, Yao Y, Jin M, Zeng XF, Qian JM. Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. J Dig Dis. 2019;20(5):256\u201361. https:\/\/doi.org\/10.1111\/1751-2980.12720.","journal-title":"J Dig Dis"},{"issue":"3","key":"2506_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5301\/jsrd.5000214","volume":"1","author":"AB Shreiner","year":"2016","unstructured":"Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J scleroderma Relat Disord. 2016;1(3):247\u201356. https:\/\/doi.org\/10.5301\/jsrd.5000214.","journal-title":"J scleroderma Relat Disord"},{"issue":"4","key":"2506_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/03009740801998754","volume":"37","author":"M Yamamoto","year":"2008","unstructured":"Yamamoto M, Takahashi H, Akaike J, Suzuki C, Naishiro Y, Yamamoto H, Imai K, Shinomura Y. Gastric antral vascular ectasia (GAVE) associated with systemic sclerosis. Scand J Rheumatol. 2008;37(4):315\u20136. https:\/\/doi.org\/10.1080\/03009740801998754.","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"2506_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/art.24730","volume":"61","author":"D Khanna","year":"2009","unstructured":"Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Care Res. 2009;61(9):1257\u201363. https:\/\/doi.org\/10.1002\/art.24730.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"2506_CR7","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3899\/jrheum.110225","volume":"38","author":"D Khanna","year":"2011","unstructured":"Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. J Rheumatol. 2011;38(9):1920\u20134. https:\/\/doi.org\/10.3899\/jrheum.110225.","journal-title":"J Rheumatol"},{"key":"2506_CR8","unstructured":"Bae S, Allanore Y, Coustet B, Maranian P, Khanna D. Development and validation of French version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. Clin Exp Rheumatol. 2011;29(2 SUPPL. 65):S15-21."},{"issue":"14","key":"2506_CR9","first-page":"61","volume":"33","author":"M Gorga","year":"2015","unstructured":"Gorga M, Mihai C, Soare AM, Dobrot\u0103 R, Gherghe AM, Stoica V. Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol. 2015;33(14):61\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"2506_CR10","first-page":"55","volume":"33","author":"R Gualtierotti","year":"2015","unstructured":"Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G, et al. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clin Exp Rheumatol. 2015;33:55\u201360.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2506_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5152\/tjg.2018.17856","volume":"30","author":"YM Ta\u015f","year":"2019","unstructured":"Ta\u015f YM, Hakim GD, Keskino\u011flu P, Kenar G, Yarkan H, Zengin B, et al. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society. Turkish J Gastroenterol. 2019;30(3):234\u201341. https:\/\/doi.org\/10.5152\/tjg.2018.17856.","journal-title":"Turkish J Gastroenterol"},{"issue":"11","key":"2506_CR12","first-page":"1985","volume":"58","author":"TF Marighela","year":"2019","unstructured":"Marighela TF, Arismendi MI, Marvulle V, Brunialti MKC, Salom\u00e3o R, Kayser C. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatol (United Kingdom). 2019;58(11):1985\u201390.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"1","key":"2506_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1340-y","volume":"19","author":"B Vigone","year":"2017","unstructured":"Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19(1):1\u20138.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2506_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","volume":"45","author":"VM Hsu","year":"2018","unstructured":"Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR. Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Rheumatol. 2018;45(3):405\u201310. https:\/\/doi.org\/10.3899\/jrheum.161040.","journal-title":"J Rheumatol"},{"issue":"6","key":"2506_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/BOR.0000000000000645","volume":"31","author":"ZH McMahan","year":"2019","unstructured":"McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol. 2019;31(6):561\u20138. https:\/\/doi.org\/10.1097\/BOR.0000000000000645.","journal-title":"Curr Opin Rheumatol"},{"key":"2506_CR16","doi-asserted-by":"crossref","unstructured":"Bates D, M\u00e4chler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1-48.","DOI":"10.18637\/jss.v067.i01"},{"issue":"2","key":"2506_CR17","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TAJ, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202\u20135.","journal-title":"J Rheumatol"},{"key":"2506_CR18","unstructured":"Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):57-63."},{"key":"2506_CR19","doi-asserted-by":"crossref","unstructured":"Abozaid HSM, Imam HMK, Abdelaziz MM, EL-Hammady DH, Fathi NA, Furst DE. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis. Semin Arthritis Rheum [Internet]. 2017;47(3):403\u20138.","DOI":"10.1016\/j.semarthrit.2017.05.005"},{"key":"2506_CR20","doi-asserted-by":"crossref","unstructured":"Abignano G, Mennillo GA, Lettieri G, Temiz Karadag D, Carriero A, Padula AA, et al. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Reflux Scale correlates with impaired Esophageal Scintigraphy findings in Systemic Sclerosis. J Rheumatol. 2021:jrheum.201283. Epub ahead of print.","DOI":"10.3899\/jrheum.201283"},{"issue":"6","key":"2506_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/gut.2009.200063","volume":"59","author":"J Dent","year":"2010","unstructured":"Dent J, Vakil N, Jones R, Bytzer P, Sch\u00f6ning U, Halling K, Junghard O, Lind T. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010 Jun;59(6):714\u201321. https:\/\/doi.org\/10.1136\/gut.2009.200063.","journal-title":"Gut."},{"issue":"2","key":"2506_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/dote.12163","volume":"28","author":"EA Bolier","year":"2015","unstructured":"Bolier EA, Kessing BF, Smout AJ, Bredenoord AJ. Systematic review: questionnaires for assessment of gastroesophageal reflux disease. Dis Esophagus. 2015;28(2):105\u201320. https:\/\/doi.org\/10.1111\/dote.12163.","journal-title":"Dis Esophagus"},{"key":"2506_CR23","first-page":"1351","volume":"67","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Kahrilas PJ. Savarino E, et al. Modern diagnosis of GERD: the Lyon ConsensusGut. 2018;67:1351\u201362.","journal-title":"Modern diagnosis of GERD: the Lyon ConsensusGut"},{"issue":"6","key":"2506_CR24","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.3892\/etm.2019.8125","volume":"18","author":"A Petcu","year":"2019","unstructured":"Petcu A, Ghib LJ, Grad SM, Popovici C, Rogojan L, Rednic N, Rednic S. Upper gastrointestinal involvement in systemic sclerosis: findings in a real-life setting. Exp Ther Med. 2019;18(6):5095\u2013100. https:\/\/doi.org\/10.3892\/etm.2019.8125.","journal-title":"Exp Ther Med"},{"issue":"1","key":"2506_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00296-010-1595-y","volume":"32","author":"R Thonhofer","year":"2012","unstructured":"Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012;32(1):165\u20138. https:\/\/doi.org\/10.1007\/s00296-010-1595-y.","journal-title":"Rheumatol Int"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02506-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T03:05:26Z","timestamp":1619060726000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2506"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02506-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-203973\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent: All patients included in the EUSTAR database have signed an informed consent form in their EUSTAR center.Ethics approval: All contributing EUSTAR centers have obtained approval from their respective ethics committee for including a patient\u2019s data in the EUSTAR database after the patient has given written informed consent. Ethical approval for this data collection and analysis was issued by the cantonal ethics (BASEC Nr. PB_2016-01515 and 2018-02165).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed on the final version of the submitted paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Norina Zampatti, Alexandru Garaiman, and Suzana Jordan: nothing to disclose.Rucsandra Dobrota has received grants\/research support from Actelion and Pfizer, outside the submitted work.Mike Oliver Becker has received consultancy fees from Bayer and Amgen, outside the submitted work.Britta Maurer had grant\/research support from AbbVie, Protagen, Novartis, congress support from Pfizer, Roche, Actelion, and MSD, and received consultancy fees from Boehringer Ingelheim, outside the submitted work. In addition, B. Maurer has a patent mir-29 for the treatment of systemic sclerosis registered.Oliver Distler has received consultancy fees from Acceleron Pharma, Amgen, AnaMar, Arxx Therapeutics, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer Ingelheim, Corbus Pharmacheuticals, ChemomAb, CSL Behring, Galapagos NV, Glenmark Pharmaceuticals, GSK, Horizon Pharmaceuticals, Inventiva, Italfarmaco, iQvia, Kymera Therapeutics, Lilly, Medac, Medscape, MSD, Novartis, Pfizer, Roche, Roivant Sciences, Sanofi, Serodapharm, Topadur, Target Bioscience and UCB, in the area of potential treatments of scleroderma and its complications, outside the submitted work. In addition, Prof. Distler had a project scoring fee from Abbvie and grants\/research support from Kymera and Mitsubishi Tanabe Pharma. He also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143).Carina Mihai has received congress support from Actelion and Roche, and personal fees from Boehringer Ingelheim, Mepha, and MEDtalks Switzerland, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}